Cordis: SUSTANE drug-eluting balloon shows 90.3% 12-month patency in SELUTION4SFA trial

Cordis reported that its SELUTION SLR SUSTANE PTA drug-eluting balloon achieved 90.3% 12-month primary patency in the SELUTION4SFA pivotal study, meeting its main efficacy goal.